Sp1 Induced Gene TIMP1 is Related to Immune Cell Infiltration in Glioblastoma

Overview

Journal Sci Rep

Specialty Science

Date 2022 Jul 1

PMID 35778451

Authors

Lu Liu

Shuyao Yang

Kefeng Lin

Xiaoman Yu

Jiaqi Meng

Chao Ma

Zheng Wu

Yuchao Hao

Ning Chen

Qi Ge

Wenli Gao

Xiang Wang

Eric W-F Lam

Lin Zhang

Fangcheng Li

Bilian Jin

Di Jin

Affiliations

Soon will be listed here.

Abstract

Tumor immune microenvironment exerts a profound effect on the population of infiltrating immune cells. Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) is frequently overexpressed in a variety of cells, particularly during inflammation and tissue injury. However, its function in cancer and immunity remains enigmatic. In this study, we find that TIMP1 is substantially up-regulated during tumorigenesis through analyzing cancer bioinformatics databases, which is further confirmed by IHC tissue microarrays of clinical samples. The TIMP1 level is significantly increased in lymphocytes infiltrating the tumors and correlated with cancer progression, particularly in GBM. Notably, we find that the transcriptional factor Sp1 binds to the promoter of TIMP1 and triggers its expression in GBM. Together, our findings suggest that the Sp1-TIMP1 axis can be a potent biomarker for evaluating immune cell infiltration at the tumor sites and therefore, the malignant progression of GBM.

Citing Articles

Glioblastoma drives protease-independent extracellular matrix invasion of microglia.

Chang C, Bale A, Bhargava R, Harley B Mater Today Bio. 2025; 31:101475.

PMID: 39896278 PMC: 11787038. DOI: 10.1016/j.mtbio.2025.101475.

Integrative bioinformatic analysis to identify potential phytochemical candidates for glioblastoma.

Usmani Rana H, Nisar H, Prajapati J, Goswami D, Rawat R, Eyupoglu V Heliyon. 2024; 10(24):e40744.

PMID: 39720087 PMC: 11665539. DOI: 10.1016/j.heliyon.2024.e40744.

Glioblastoma Tumor Microenvironment: An Important Modulator for Tumoral Progression and Therapy Resistance.

Tataranu L, Turliuc S, Kamel A, Rizea R, Dricu A, Staicu G Curr Issues Mol Biol. 2024; 46(9):9881-9894.

PMID: 39329940 PMC: 11430601. DOI: 10.3390/cimb46090588.

Radiogenomic biomarkers for immunotherapy in glioblastoma: A systematic review of magnetic resonance imaging studies.

Ghimire P, Kinnersley B, Karami G, Arumugam P, Houlston R, Ashkan K Neurooncol Adv. 2024; 6(1):vdae055.

PMID: 38680991 PMC: 11046988. DOI: 10.1093/noajnl/vdae055.

The genes significantly associated with an improved prognosis and long-term survival of glioblastoma.

Yoon H, Cheong J, Ryu J, Won Y, Min K, Han M PLoS One. 2023; 18(11):e0295061.

PMID: 38019838 PMC: 10686432. DOI: 10.1371/journal.pone.0295061.

References

Vizcaino C, Mansilla S, Portugal J . Sp1 transcription factor: A long-standing target in cancer chemotherapy. Pharmacol Ther. 2015; 152:111-24. DOI: 10.1016/j.pharmthera.2015.05.008. View

Bockelman C, Beilmann-Lehtonen I, Kaprio T, Koskensalo S, Tervahartiala T, Mustonen H . Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer. BMC Cancer. 2018; 18(1):679. PMC: 6013876. DOI: 10.1186/s12885-018-4589-x. View

Engelhardt B, Vajkoczy P, Weller R . The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017; 18(2):123-131. DOI: 10.1038/ni.3666. View

Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T . Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2017; 20(1):66-77. PMC: 5761527. DOI: 10.1093/neuonc/nox132. View

Chiefari E, Brunetti A, Arturi F, Bidart J, Russo D, Schlumberger M . Increased expression of AP2 and Sp1 transcription factors in human thyroid tumors: a role in NIS expression regulation?. BMC Cancer. 2002; 2:35. PMC: 139985. DOI: 10.1186/1471-2407-2-35. View

Pan L, Wang H, Luo J, Zeng J, Pi J, Liu H . Epigenetic regulation of TIMP1 expression by 8-oxoguanine DNA glycosylase-1 binding to DNA:RNA hybrid. FASEB J. 2019; 33(12):14159-14170. PMC: 6894084. DOI: 10.1096/fj.201900993RR. View

Wierstra I . Sp1: emerging roles--beyond constitutive activation of TATA-less housekeeping genes. Biochem Biophys Res Commun. 2008; 372(1):1-13. DOI: 10.1016/j.bbrc.2008.03.074. View

Fan C, Zhang X, Zhang P, Zhao J, Shen H, Zhang Y . LPS stimulation during HCV infection induces MMP/TIMP1 imbalance in macrophages. J Med Microbiol. 2020; 69(5):759-766. PMC: 7451043. DOI: 10.1099/jmm.0.001185. View

Hsu T, Wang M, Chen S, Yeh Y, Su W, Chang W . Sp1 expression regulates lung tumor progression. Oncogene. 2011; 31(35):3973-88. PMC: 3432230. DOI: 10.1038/onc.2011.568. View

10.

Seubert B, Grunwald B, Kobuch J, Cui H, Schelter F, Schaten S . Tissue inhibitor of metalloproteinases (TIMP)-1 creates a premetastatic niche in the liver through SDF-1/CXCR4-dependent neutrophil recruitment in mice. Hepatology. 2014; 61(1):238-48. PMC: 4280301. DOI: 10.1002/hep.27378. View

11.

Schmitt M, Sweep F . Tissue inhibitor metalloproteinase type-1 (TIMP-1), a novel cancer biomarker predicting response of adjuvant anthracycline-based chemotherapy in patients afflicted with primary breast cancer. Eur J Cancer. 2009; 45(14):2444-6. DOI: 10.1016/j.ejca.2009.07.001. View

12.

Butt A, Mills K . Immunosuppressive networks and checkpoints controlling antitumor immunity and their blockade in the development of cancer immunotherapeutics and vaccines. Oncogene. 2013; 33(38):4623-31. DOI: 10.1038/onc.2013.432. View

13.

Jarnicki A, Lysaght J, Todryk S, Mills K . Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol. 2006; 177(2):896-904. DOI: 10.4049/jimmunol.177.2.896. View

14.

Hawthorn L, Stein L, Varma R, Wiseman S, Loree T, Tan D . TIMP1 and SERPIN-A overexpression and TFF3 and CRABP1 underexpression as biomarkers for papillary thyroid carcinoma. Head Neck. 2004; 26(12):1069-83. DOI: 10.1002/hed.20099. View

15.

Ostrom Q, Gittleman H, Xu J, Kromer C, Wolinsky Y, Kruchko C . CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. Neuro Oncol. 2017; 18(suppl_5):v1-v75. PMC: 8483569. DOI: 10.1093/neuonc/now207. View

16.

Hsu J, Chang T, Lee G, Lee T, Chen C . Identification of potential biomarkers related to glioma survival by gene expression profile analysis. BMC Med Genomics. 2019; 11(Suppl 7):34. PMC: 7402580. DOI: 10.1186/s12920-019-0479-6. View

17.

Letovsky J, Dynan W . Measurement of the binding of transcription factor Sp1 to a single GC box recognition sequence. Nucleic Acids Res. 1989; 17(7):2639-53. PMC: 317648. DOI: 10.1093/nar/17.7.2639. View

18.

Jackson H, Defamie V, Waterhouse P, Khokha R . TIMPs: versatile extracellular regulators in cancer. Nat Rev Cancer. 2016; 17(1):38-53. DOI: 10.1038/nrc.2016.115. View

19.

Slater E, Fendrich V, Strauch K, Rospleszcz S, Ramaswamy A, Matthai E . LCN2 and TIMP1 as Potential Serum Markers for the Early Detection of Familial Pancreatic Cancer. Transl Oncol. 2013; 6(2):99-103. PMC: 3610554. DOI: 10.1593/tlo.12373. View

20.

Zhao C, Meng A . Sp1-like transcription factors are regulators of embryonic development in vertebrates. Dev Growth Differ. 2005; 47(4):201-11. DOI: 10.1111/j.1440-169X.2005.00797.x. View